Figure 3.
Treatment effect on the primary outcome according to baseline hematocrit categories. Canagliflozin did not significantly reduce the risk of the primary outcome in either males (HR, 0.97; 95% CI, 0.86-1.10) or females (HR, 0.95; 95% CI, 0.78-1.15). In males, baseline hematocrit categories significantly modified the treatment effect on the primary outcome (P interaction < .01), with particularly pronounced benefits observed in anemic patients (HR, 0.64; 95% CI, 0.49-0.85). In contrast, no effect modification by baseline hematocrit levels was observed in females (P interaction = .59). The event rate was presented as the number of events per 1000 person-years. ∗Anemia was defined as a hematocrit level of <39% in males or <36% in females. †Erythrocytosis was defined as a hematocrit level of >49% in males or >48% in females.

Treatment effect on the primary outcome according to baseline hematocrit categories. Canagliflozin did not significantly reduce the risk of the primary outcome in either males (HR, 0.97; 95% CI, 0.86-1.10) or females (HR, 0.95; 95% CI, 0.78-1.15). In males, baseline hematocrit categories significantly modified the treatment effect on the primary outcome (P interaction < .01), with particularly pronounced benefits observed in anemic patients (HR, 0.64; 95% CI, 0.49-0.85). In contrast, no effect modification by baseline hematocrit levels was observed in females (P interaction = .59). The event rate was presented as the number of events per 1000 person-years. ∗Anemia was defined as a hematocrit level of <39% in males or <36% in females. †Erythrocytosis was defined as a hematocrit level of >49% in males or >48% in females.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal